STOCK TITAN
  1. Home
  2. Sec-filings
  3. ERNA
  4. [8-K] Ernexa Therapeutics Inc. Reports Material Event

Ernexa Therapeutics (ERNA) finance SVP resigns, will aid transition

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. announced that Senior Vice President of Finance Sandra Gurrola has submitted her resignation, effective July 3, 2026. The company states that her resignation is not due to any disagreement over operations, policies, or practices.

After her resignation becomes effective, Ms. Gurrola has agreed to provide transition assistance on a part-time basis for up to 10 hours per week through the filing of Ernexa’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Ernexa has begun a search for her successor and plans to use additional outside support to help with finance, accounting, and reporting until a replacement is appointed.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Resignation notice date June 22, 2026 Date Sandra Gurrola delivered resignation notice
Resignation effective date July 3, 2026 Date SVP of Finance resignation becomes effective
Transition assistance hours Up to 10 hours per week Part-time support after resignation effective date
Transition period anchor Quarter ended June 30, 2026 Transition continues through filing of Form 10-Q
transition assistance financial
"Ms. Gurrola has agreed to provide transition assistance to the Company on a part-time basis"
Quarterly Report on Form 10-Q regulatory
"through the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026"
A quarterly report on Form 10-Q is a standardized financial filing public companies must submit to U.S. regulators every three months, summarizing recent financial results, cash flows, balance sheet changes, operations and material risks or legal developments. Investors treat it like a company report card that shows up-to-date facts rather than marketing copy, helping them track performance, spot trends, reassess risk and make buy or sell decisions.
material compensatory arrangement financial
"If the Company enters into or approves a material compensatory arrangement with Ms. Gurrola"
principal executive offices other
"(Address of Principal Executive Offices)"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0000748592 0000748592 2026-06-22 2026-06-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 22, 2026

 

Ernexa Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-11460   31-1103425
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

1035 Cambridge Street, Suite 18A    
Cambridge, MA   02141
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (617) 798-6700

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock, par value $0.005 per share   ERNA   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 22, 2026, Sandra Gurrola, Senior Vice President of Finance of Ernexa Therapeutics Inc., a Delaware corporation (the “Company”), delivered her notice of resignation, with such resignation becoming effective July 3, 2026. Ms. Gurrola’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

Following the effective date of her resignation, Ms. Gurrola has agreed to provide transition assistance to the Company on a part-time basis for up to 10 hours per week through the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. The Company has not yet determined the compensation, if any, payable to Ms. Gurrola for such transition services. If the Company enters into or approves a material compensatory arrangement with Ms. Gurrola in connection with her resignation or transition services, the Company will disclose such arrangement in accordance with applicable SEC rules.

 

The Company has initiated a search to identify a successor. Until a successor is appointed, the Company expects to use additional outside support to assist with finance, accounting, and reporting matters.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-2-
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Ernexa Therapeutics Inc.
     
Dated: June 26, 2026 By: /s/ Sanjeev Luther
    Sanjeev Luther
    President and Chief Executive Officer

 

-3-

Source: View Original Filing on SEC EDGAR

FAQ

What executive change did Ernexa Therapeutics (ERNA) disclose?

Ernexa Therapeutics disclosed that Senior Vice President of Finance Sandra Gurrola has resigned, effective July 3, 2026. She will continue supporting the company part-time during a transition period while Ernexa searches for a successor and supplements its finance function with outside support.

When does the Ernexa Therapeutics (ERNA) SVP of Finance resignation take effect?

The resignation of Ernexa Therapeutics’ Senior Vice President of Finance, Sandra Gurrola, becomes effective on July 3, 2026. She submitted her notice on June 22, 2026 and will provide part-time transition assistance after that date while the company recruits a replacement.

What transition role will the departing Ernexa (ERNA) SVP of Finance have?

After her resignation is effective, Sandra Gurrola will provide transition assistance to Ernexa Therapeutics on a part-time basis. She agreed to work up to 10 hours per week through the filing of Ernexa’s Form 10-Q for the quarter ended June 30, 2026.

How will Ernexa Therapeutics (ERNA) handle finance functions after the SVP resigns?

Ernexa Therapeutics has initiated a search for a new finance leader and expects to use additional outside support in the interim. External resources will help cover finance, accounting, and reporting needs while the company conducts its recruitment process for a permanent successor.

Will Ernexa Therapeutics (ERNA) disclose any transition compensation for the SVP of Finance?

Ernexa Therapeutics has not yet determined what compensation, if any, will be paid to Sandra Gurrola for transition services. The company indicated it will disclose any material compensatory arrangement related to her resignation or transition assistance in accordance with applicable SEC requirements.

Filing Exhibits & Attachments

3 documents

Other Documents